Form 4: Jazz Pharmaceuticals Director Trades Ordinary Shares
Statement of Changes in Beneficial Ownership
Jazz Pharmaceuticals plc reports a transaction by Director Seamus Mulligan involving the acquisition of ordinary shares and the exercise of a stock option.
Summary
- Seamus Mulligan, a Director at Jazz Pharmaceuticals plc, acquired 3,415 ordinary shares on May 28, 2026, at a price of $138.08 per share.
- Mulligan also exercised a non-qualified stock option for 3,415 ordinary shares on the same date.
- Following these transactions, Mulligan directly beneficially owns 1,183,028 ordinary shares.
- Additionally, 101,621 ordinary shares are beneficially owned indirectly by Nerano Pharma Limited, an entity controlled by Mulligan and his family.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine transaction by a director exercising stock options and acquiring shares, which is a common occurrence and does not inherently signal a significant change in the company's prospects.
Positives
- Director Seamus Mulligan's acquisition of shares indicates confidence in the company's value.
- The exercise of stock options suggests that the stock price is at or above the option strike price, potentially indicating positive performance or outlook.
Future Outlook
No specific forward-looking statements or guidance were provided in this filing, which solely reports a change in beneficial ownership.
Industry Context
StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are common disclosures in the pharmaceutical and biotechnology sectors. These filings provide transparency regarding executive and director holdings and transactions, which can be monitored by investors for potential signals of confidence or divestment.
Related Party Transactions
- Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person (Seamus Mulligan) and his immediate family.
Stakeholder Impact
- Shareholders: The transaction provides transparency into director holdings and activity, which can inform investment decisions.
- Management: The acquisition of shares by a director may signal confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 05/28/2026 | Transaction Date for acquisition of ordinary shares and exercise of stock option. |
| 08/10/2026 | Earliest transaction date mentioned in the filing. |
| 08/11/2016 | Grant date of the non-qualified stock option. |
| 09/01/2016 | Start date of the vesting period for the stock option. |
| 08/01/2017 | End date of the vesting period for the stock option. |
| 06/01/2026 | Date of signature for the filing. |
Keywords
Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Stock Option, Ordinary Shares, Beneficial Ownership, Director Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.